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Background: The standard of care for increasing kerati-
nized gingiva adjacent to teeth that do not require root cover-
age is the free gingival graft (FGG). A pilot study indicated that
the use of a living cellular construct (LCC) could be effective in
this clinical scenario.
Methods: A pivotal, multicenter, randomized,within-patient,
controlled, open-label trial was conducted (N = 96 patients). Af-
ter removing the mucosa and keratinized gingiva from the test
site, either an LCC or FGG was applied. The primary efficacy
endpoint was the ability of the LCC to regenerate ‡2 mm kera-
tinized gingiva at 6 months. Secondary measures were the
same color and texture as the adjacent tissue, a 1-mm width
of keratinized gingiva at 6 months, patient treatment prefer-
ence, surgical site sensitivity at 1 week, and patient-reported
pain after 3 days. Safety was assessed by reports of adverse
events.
Results: At 6 months, the LCC regenerated ‡2 mm of
keratinized gingiva in 95.3% of patients (81 of 85 patients;
P <0.001 versus a 50% predefined standard). As expected,
the FGG generated more keratinized gingiva than the LCC
(4.57 – 1.0 mm versus 3.2 – 1.1 mm, respectively). The
gingiva regenerated with the LCC matched the color and
texture of the adjacent gingiva. All patients achieved ‡1 mm
keratinized gingiva with the LCC treatment by 6 months, and
more patients preferred treatment with the LCC than with
the FGG. No difference in sensitivity or pain was noted be-
tween the treatments. The treatments were well tolerated,
and reported adverse events were typical for this type of
periodontal surgery.
Conclusion: The use of an LCC may provide a safe and ef-
fective therapy for augmenting the zone of keratinized gingiva.
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M
ost clinicians agree that it is
preferable to have keratinized
gingiva adjacent to teeth. The
presence of keratinized gingiva may make
homecare more effective, resist frenum
pull, and potentially reduce further re-
cession.1,2 The absence of an adequate
keratinized mucosa has been associated
with high plaque accumulation and gingi-
val inflammation.3 If a decision is made to
increase the zone of the keratinized gin-
giva, the standard of care for non–root-
coverage techniques has been the free
gingival graft (FGG). As a graft, the palatal
tissue provides keratinized gingiva, but it
retains its palatal phenotype and may be
noticeably different in color and texture
from the surrounding gingival tissue. Most
importantly, the need for a donor site adds
to the morbidity (e.g., pain and bleeding)
of the procedure for the patient.
A living cellular construct (LCC) com-
prised of human allogenic fibroblasts,
keratinocytes, bovine collagen, and hu-
man extracellular matrix proteins has
been used for >10 years to treat patients
with cutaneous wounds, including venous
leg4 and diabetic foot ulcers,5,6 excised
burn wounds,7 and excisional surgery.8-12
Because of the similarities of healing
between cutaneous and oral mucosal
wounds, it was thought that LCC may
deliver better results than the standard
FGG in terms of the color and texture
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of the gingiva while providing an adequate amount
of new keratinized gingiva.
Although the mechanism of action of the LCC has
not been fully elucidated, it has been postulated that
it improves the wound environment through growth
factor interactions, matrix deposition and degradation,
wound coverage, and the provision of responsive
cells.13 It has been established that LCC does not
function as an autograft,14 which normally vascular-
izes, integrates, and persists in situ, retaining the
characteristics of the tissue of origin; instead, the
LCC appears to stimulate the patient’s own cells to
regenerate site-appropriate tissue through the mod-
ulation and improvement of secondary intention
healing.7,9,10,12,15 The LCC produces cytokines and
cell growth factors involved in tissue development
and wound healing (e.g., vascular endothelial growth
factor, platelet-derived growth factor, bone morpho-
genetic protein 2, and transforming growth factor
b).6,16 Despite being comprised of allogenic cells,
numerous studies4,5,7-12,14,15,17 have determined
that the LCC does not elicit an immune reaction.
Results from a single-center, randomized, within-
patient, controlled pilot study15 with an aim similar to
this randomized controlled trial suggested that treat-
ment with the LCC was not statistically significantly
different from FGG in terms of recession, clinical at-
tachment level (CAL), bleeding on probing (BOP), re-
sistance to muscle pull, or inflammation. At 6 months,
the LCC generated 2.4 – 1.0 mm of keratinized gin-
giva, without a donor site. However, the LCC provided
a statistically significantly better color match and
texture than the FGG (P <0.001), and patients pre-
ferred the LCC more than FGG (P = 0.041). None of
the data from the pilot study15 was included in the
present report.
The present study is designed to determine whether
the LCC could achieve a clinically acceptable, safe,
and effective amount of keratinized gingiva (‡2 mm)
6 months after surgery in patients who had an insuf-
ficient zone of attached gingiva (defined as <1 mm
attached gingiva) associated with ‡2 non-adjacent
teeth. Although ‡2 mm keratinized gingiva (generally
corresponding to 1 mm attached gingiva) has been
suggested to be required to maintain gingival health,18
no single clinical measures are universally accepted to
assess periodontal treatment outcomes.19 Thus, we
designed a study with one primary and six secondary
endpoints that reflected the most commonly used
factors that periodontists consider when determining
the clinical effectiveness of mucogingival treatment.
MATERIALS AND METHODS
Patients
The study protocol was approved by institutional
review boards of participating sites (Perio Health
Professionals, Houston, TX; Boston Periodontics and
Dental Implants, Boston, Massachusetts; Michigan
Center for Oral Research, University of Michigan
School of Dentistry, Ann Arbor, MI; and University
of Texas Health Science Center, San Antonio, Texas),
and all patients gave written informed consent before
any study-related procedures were done. Patients
were eligible for inclusion in the study if they had: 1)
‡18 and £70 years of age, and 2) ‡2 non-adjacent
teeth in contralateral quadrants of the same jaw with
£1 mm attached gingiva that required soft tissue graft-
ing without the need for root coverage. Other inclusion
and exclusion criteria are provided in Table 1.
Study Product
The LCC# is comprised of a device component (col-
lagen matrix) and biologic components (cells and
their products) supplied as a single circular construct
75 mm in diameter and 0.75 mm thick on a semi-
permeable polycarbonate membrane on top of an
agarose-rich nutrient medium. The LCC was stored
at room temperature.
Study Design
This study was a pivotal, multicenter, randomized,
within-patient, controlled, open-label, treatment-
comparison study designed to establish the superior-
ity for predefined efficacy endpoints. After screening,
two contralateral teeth were randomly assigned to
treatment with the LCC or an FGG as indicated by
a predetermined computer-generated randomization
scheme. Treatment assignments were stored in
sealed envelopes for each patient and opened only
at the time of the procedure. As many as three teeth
per quadrant were treated, but only one tooth in each
quadrant was identified as the study tooth. When two
teeth were selected, the study tooth was identified be-
fore surgery; when three teeth were selected, the study
tooth was the middle tooth. The criteria for selecting
target teeth were teeth relatively matched in terms
of recession, BOP, width of keratinized tissue, prob-
ing depth (PD), and CAL. Baseline measurements
were taken for standard periodontal treatment
(e.g., plaque score, BOP, PD [using a standardized
periodontal probe], keratinized gingiva width, and
inflammation). Because of the nature of the control
treatment (i.e., FGG), investigators (MKM, ETS, MN,
RN, DLC, JTM) and patients could not be masked to
the study-tooth treatment assignment or order of sur-
gical procedures. Thus, all clinical measurements
were taken by calibrated independent examiners
(not the surgeons) at each treatment center in an at-
tempt to reduce the bias. Before study sites began
enrolling patients, periodontal examiners were identi-
fied and participated in a calibration training session
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to evaluate the intra- and interexaminer variability
for PD, recession depth, and identification of the
mucogingival junction. Levels of both intra- and in-
terexaminer variability were found to be within prespe-
cified limits (k ‡0.7 for interexaminer comparisons
and k ‡0.9 for intraexaminer comparisons).
Surgery
On day 0, patients were treated with the LCC on one
study tooth and the FGG on the contralateral tooth.
Recipient beds were created according to standard
procedures that ensured no muscle tension on the
bed.20,21 The size of the LCC was determined by the
investigator and was based upon the number of teeth
being treated with the LCC. The LCC was Z-folded
(Fig. 1) with minimum dimensions of 6 mm wide
and 10 mm long. The size of the FGG applied was
4 mm wide, with the length dictated by the number
of teeth being treated. The details of the surgical pro-
cedure have been previously reported.15 In brief, after
the patients received anesthesia with 2% lidocaine
hydrochloride, a partial-thickness dissection was per-
formed to remove any keratinized gingival mucosa
and non-keratinized alveolar mucosa from the site.
A coronal incision was made at the height of the exist-
ing mucosa that extended at least to the line angle of
adjacent teeth, and from that point, vertical incisions
were made on mesial and distal aspects of study sites
to allow ‡7 mm apical to the base of the recession. Me-
sial and distal incisions were connected apically, and
any muscle fibers were removed to create a clean
periosteal bed. If feasible, a full-thickness horizontal
incision was made just apical to the planned level
of the LCC or FGG placement. In this way, the sepa-
ration of the apical periosteum from the coronal peri-
osteum was accomplished to reduce the risk of the
retraction of the treated area during healing.
The graft was harvested from the palatal donor site
according to standard practices.21 A partial-thick-
ness (i.e.,1 to 2 mm deep) incision was used to har-
vest a graft the size of the recipient bed. The palatal
donor site was covered with surgical dressing**
which remained until it fell off on its own or was re-
moved at the 1- or 2-week follow-up visit.
Coverage of Wound Bed
The LCC was prepared in a Z-fold with the keratino-
cyte cell layer facing out and was trimmed to the
size needed and applied to the wound bed within 15
minutes after removal from the storage bag. The
LCC was sutured in place at each papilla (Fig. 1).
An additional single layer of the LCC that extended lat-
erally beyond the wound margins was placed over the
entire preparation and sutured at the four corners,
when possible. The surgical area was placed under
tension to confirm that it was free of movement.
The harvested FGG was placed directly on the re-
cipient wound bed and sutured in place using stan-
dard FGG techniques.21 Both treatment areas were
covered with surgical dressing until it fell off on its
own or was removed at the 1- or 2-week follow-up visit.
Follow-Up Care
Patients were prescribed antibiotics in accordance
with local standards of care and were provided with
a 0.12% solution of chlorhexidine mouthrinse and
Table 1.
Inclusion and Exclusion Criteria for
Enrollment in the Study
Inclusion requirements
‡18 and £70 years of age
‡2 non-adjacent teeth in contralateral quadrants of the
same jaw with £1 mm attached gingiva that required
soft tissue grafting
Root coverage not desired
Exclusion requirements
Class III recession in the presence of a shallow vestibule
or Class IV recession
Vestibule depth <7 mm from the base of recession
Systemic condition, such as diabetes mellitus, HIV, cancer,
or bone metabolic disease that could compromise wound
healing
Treatment with systemic corticosteroids, immunosuppressive
agents, radiation therapy, or chemotherapy within
2 months of enrollment in the study
Acute infectious lesions in intended surgical areas
Received intravenous or intramuscular bisphosphonates
Tobacco use within 3 months of enrollment in the study
Only molar teeth suitable for soft-tissue grafting
Miller grade ‡2 mobility
Known hypersensitivity to bovine collagen or iodine
(shellfish allergy)
Previous treatment with an LCC or any skin graft product
at the target site or immediately adjacent to it
Pregnancy
HIV = human immunodeficiency virus.
Figure 1.
The LCC arranged in a Z-fold fashion (A) and placed over an oral defect
in which the mucosal and keratinized gingiva was removed (B). (1A:
figure prepared for, and exclusively licensed to, Organogenesis by Mark
Lefkowitz; 1B: figure prepared for, and exclusively licensed to,
Organogenesis by Levent Efe.)
** Coe-Pak, GC America, Alsip, IL.
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postoperative oral hygiene instructions. Patients were
to contact the investigational site if the surgical dress-
ing fell off before the first follow-up visit (at 1 week).
Patients maintained a diary for 1 to 14 days, noting
the adherence of the surgical dressing at surgical sites
and at the site of the palatal tissue donation, assessing
pain, and recording any medications taken for pain.
Follow-up visits occurred at 1 and 4 weeks and 3
and 6 months after surgery. A visit at week 2 was re-
quired if the surgical dressing remained at any site at
the week-1 visit. Changes in medications and adverse
events were recorded at all visits; photographs of
treatment sites were taken, clinical measurements
were obtained, and the color and texture of test sites
were evaluated. An oral exam was done at 4 weeks
and 6 months, and dental prophylaxis was provided
at 3 and 6 months. At the 6-month visit, a patient
treatment-preference questionnaire was completed,
radiographs of study teeth were taken, and a pregnancy
test was given to women of childbearing potential.
Study Endpoints
The primary efficacy endpoint was the ability of the
LCC treatment to regenerate ‡2 mm keratinized gin-
giva at 6 months. Secondary measures of efficacy
were: color the same as the adjacent tissue (visually
evaluated), texture (i.e., firmness) the same as adja-
cent tissue (tactually evaluated), width of keratinized
gingiva at 6 months ‡1 mm, patient treatment prefer-
ence which was related to the procedure and out-
come, report of surgical site sensitivity (in response
to a puff of air) at 1 week, and pain after 3 days. The
primary measures of safety included adverse events
(overall and mouth-specific and treatment-specific
events). Adverse events were reported using a med-
ical dictionary.†† Additional 6-month endpoints that
were prospectively measured included the width (in
millimeters) of keratinized gingiva and attached gin-
giva regenerated.
Statistical Analyses
Statistical analyses were prospectively defined. The
power was calculated based on achieving 85% power
for the primary endpoint. A sample size of 74 patients
was required to achieve this power. No interim analysis
wasdone.The treatment randomizationwasdetermined
using a computer-generated randomization scheme
that included the type of treatment used on each side
and the order of the treatment implementation.
Allpatients randomlyassigned to treatments, treated,
and followed for ‡1 week were included in the safety
assessment. The first two patients treated by each sur-
geon (11 patients) were treated for training in material
handling and standardization purposes only. Five sur-
geonscompleted trainingwith twopatients, andonesur-
geon performed one training case. Data from these
patients were included in safety-related analyses but
omitted from efficacy analyses. The efficacy population
(modified intention-to-treat [mITT]population) included
all patients with the exception of those included in the
study for training purposes. Continuous variables were
summarized using descriptive statistics (i.e., the mean,
median, SD, minimum, and maximum) and categoric
variables were summarized using frequencies and per-
centages.
The primary endpoint tested whether ‡50% of pa-
tients achieved a ‡2-mm keratinized gingiva thresh-
old at 6 months by using an exact binomial test
with a type I error rate of 0.05. The success threshold
of 50% of patients was prespecified during discussions
with the United States Food and Drug Administration,
Silver Spring, Maryland. Secondary endpoints were
tested using a closed testing strategy in which the or-
der of testing was prespecified. Each test was con-
ducted sequentially at the 0.05 level until a test was
found not to be statistically significant. Endpoints
for color and texture compared the tissue at the sur-
gical site with the adjacent non-treated tissue (su-
periority at 6 months). For a band of keratinized
gingiva ‡1 mm, the endpoint was the superiority
versus a prespecified standard empirically chosen
of 80%. The patient preference for treatment and
endpoints of surgical site sensitivity of mild or absent
after 1 week and pain absent after 3 days were su-
periority tests between treatments. The patient ques-
tionnaire was not validated; however, the study staff




The study commenced in October 2007, and the last
patient visit was in December 2008. A total of 119 pa-
tients at four sites in the United States were screened,
with 96 patients randomly assigned and treated (Fig.
2). Of the 96 patients assigned to treatment, 11 patients
were considered training patients and included in
the safety data analyses only. The numbers of patients
enrolled from investigative sites were as follows: Perio
Health Professionals (n = 34), Boston Periodontics and
Dental Implants (n = 30), Michigan Center for Oral
Research (n = 29), and University of Texas Health
Science Center (n = 3). Consistent with study inclu-
sion criteria, all patients had mucogingival defor-
mities at the time of surgery, with no other clinically
remarkable findings upon oral examinations (Table
2). All 96 patients completed the study (to month 6).
Surgery
The study surgery was completed under appropri-
ate surgical conditions at all sites. The surgical
†† Medical Dictionary for Regulatory Activities (MedDRA) v.10.0 coding
program, Cerner Corporation, Kansas City, MO.
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procedures, including training cases, were performed
on the mandible in 89 (93%) patients, with the LCC be-
ing applied to the right side in 50 (52%) patients. All
patients tolerated surgery well. Most surgical proce-
dures used the cemento-enamel junction as the refer-
ence point (LCC: 72%; FGG: 66%). Mean and median
alveolar bone levels and surgical position margins
were similar between both sides of the mouth for
any given patient. Additional baseline characteristics
of surgical sites are provided in Table 3.
Lengths of palatal grafts ranged from 8 to 30 mm,
with widths 4 mm in all but two patients who had
grafts with widths 5 mm. Lengths of LCC were sim-
ilar to those reported for palatal grafts, but widths
varied from 5 to 20 mm. No patient required a reappli-
cation of LCC or surgical dressing during the study. In
one patient, the palatal graft was taken from the side
of the mouth treated with the LCC.
Efficacy
Regeneration of keratinized gingiva at 6 months. At
the 6-month visit in 81 of 85 (95.3%) patients, the
sites that were treated with the LCC had regenerated
a clinically relevant width of keratinized gingiva (i.e.,
‡2 mm) compared to the 50% standard (P <0.001;
exact binomial test; 95% confidence interval [CI]:
88.4% to 98.7%). As expected,
the FGG generated statistically
significantly (P <0.001) more ker-
atinized gingiva than the LCC
(4.57 – 1.0 mm versus 3.21 –
1.1 mm, respectively). The four
(4.7%) patients who did not
achieve keratinized gingiva ‡2
mm achieved a width ‡1 mm (Ta-
ble 4). All patients in the mITT
population achieved ‡1 mm kera-
tinized gingiva with the LCC treat-
ment by 6 months, significantly
exceeding the standard estab-
lished at the beginning of the
study, which stipulated that ‡80%
of patients should have achieved
‡1 mm keratinized gingiva (LCC:
P <0.001, exact binomial test;
95% CI: 95.8% to 100.0%). Figure
3 provides a photographic depic-
tion of the results achieved with
both treatments.
Although not defined as a pri-
mary or secondary endpoint, the
amount of attached gingiva gener-
ated was captured. At 6 months,
sites treated with the LCC gener-
ated 1.77 – 1.32 mm attached gin-
giva, whereas the FGG sites had
3.17 – 1.17 mm attached gingiva.
Color. The color of both treated recipient sites
was compared to the adjacent, non-treated gingiva
at 4 weeks and 3 and 6 months, and the endpoint as-
sessed whether the color was the same as adjacent
tissue at 6 months. At all time points, the gingiva
of the tooth treated with the LCC was scored as
equally red (i.e., the same) as the adjacent gingiva
more often than the gingiva of the tooth treated with
the FGG (Table 5). At month 6, a significantly larger
proportion of patients treated with the LCC, com-
pared to the FGG, achieved a color that was compa-
rable with the color of the adjacent tissue (P <0.001;
McNemar test).
Texture. The texture of both treated recipient sites
was compared to the adjacent, non-treated tissue at 4
weeks and 3 and 6 months and assessed whether the
firmness was equivalent to the adjacent tissue at 6
months. At all time points, the gingiva of the tooth
treated with the LCC was scored as equally firm as
the adjacent gingiva more often than the gingiva of
the tooth treated with the FGG (Table 5). At 6 months,
a significantly larger proportion of patients treated
with the LCC, compared to the FGG, achieved a tex-
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Patient preference. At 6 months, more patients
preferred the LCC treatment compared to the
FGG treatment (71.8% versus 28.2%, respectively;
P <0.001; 95% CI: 61.0% to 81.0%). At 6 months,
more patients in the mITT population preferred
the appearance of the LCC compared to the FGG
site (76.5% versus 23.5%, respectively; P <0.001;
exact binomial test; 95% CI: 66.0% to 85.0%).
Surgical site sensitivity. The sensitivity at the pal-
atal graft site and both treatment sites after 1 week
was not frequently reported in the study population.
No sensitivity was noted in >70% of patients at any site
after 1 week, and no patient reported a severe sensi-
tivity at any site at any evaluation period. No differ-
ence in sensitivity was noted between the LCC site
and FGG site (data not shown).
Pain. More than one-half of the patients reported
some pain at one of the procedure sites (palatal graft,
LCC, or FGG) for the first 6 days of self-assessment, as
recorded in daily diaries. Although pain at the treat-
ment site was reported more frequently by patients
at the LCC site compared to the FGG site at 3 days
(70.6% versus 62.3%, respec-
tively) and 7 days (45.9%
versus 37.7%, respectively),
differences between groups
were not statistically signi-
ficant. Most of the pain was
reported as being mild or
moderate; <5% of patients
at any time point reported pain
as severe. Pain was reported
at the palatal graft site in
43.6% of patients on day 1,
and >35% of patients contin-
ued to report pain at this site
on days 2 through 4, with
some patients reporting pain
at day 12. Other measurements
taken at baseline (e.g., plaque
score, BOP, PD, and inflamma-
tion) were unremarkable (data
not shown).
Safety. All treatments were
well tolerated in this patient
population, and events re-
ported were typical of those in
patients undergoing this type
of periodontal surgery. Be-
cause of the localized applica-
tion of the LCC, adverse events
were summarized by the event
location (i.e., LCC, FGG, or
palatal graft, mouth, or other;
Table 6).
A total of 24 of 96 (25%)
patients reported ‡1 adverse event during the study,
with a total of 43 events reported, with most events re-
ported as mild or moderate in severity. No event was
reported by >2 patients. The most commonly reported
events were infections (10 events in eight [8.3%] pa-
tients) and included nasopharyngitis, respiratory tract
infection, sinusitis, and upper respiratory tract infec-
tion (n = 2 each). Eight patients reported nine gastro-
intestinal events, including two reports each of
aphthous stomatitis and dental caries. Three patients
reported an adverse event occurring at the LCC-
treated site. Two of these events were secondary to
the inadvertent placement of the polycarbonate mem-
brane on which the LCC was supplied, and the third
was a mouth ulceration. Two patients experienced
adverse events occurring at the palatal harvest site
(a postprocedural hemorrhage and thrombosis),
and two patients experienced adverse events oc-
curring at the FGG-treated site (gingivitis and skin
exfoliation).
Three serious adverse events were reported during
the study and required hospitalization: one each for
Table 2.
Demographic and Clinical Characteristics of Patients
at Baseline by Cohort
Characteristic Efficacy* (n = 85) Training (n = 11) Total (n = 96)
Sex (n [%])
Female 46 (54) 6 (55) 52 (54)
Male 39 (46) 5 (45) 44 (46)
Age (years) (n [%])
Mean (SD) 46.9 (12.7) 49.4 (16.7) 47.1 (13.1)
Median 48.3 53.6 48.8
Minimum, maximum 18.0, 70.8 21.2, 70.3 18.0, 70.8
Race (n [%])
White 77 (91) 10 (91) 87 (91)
Black 1 (1) 0 (0) 1 (1)
Asian 4 (5) 1 (9) 5 (5)
Other 3 (3) 0 (0) 3 (3)
Previous tobacco use (n [%])
Yes 34 (40) 4 (36) 38 (40)
No 51 (60) 7 (64) 58 (60)
Selected dental history (n [%])†
None 12 (14.1) 0 (0) 12 (12.5)
Loose teeth 14 (16.5) 4 (36.4) 18 (18.8)
Bleeding gums 29 (34.1) 3 (27.3) 32 (33.3)
Grinding/clenching 42 (49.4) 5 (45.5) 47 (49.0)
Sores in mouth 17 (20.0) 2 (18.2) 19 (19.8)
Previous periodontal work (n [%])
Yes 58 (68) 9 (82) 67 (70)
No 27 (32) 2 (18) 29 (30)
* Included all patients except those included in study training.
† Only clinically relevant parameters are presented.
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pneumonia, chest pain, and metastatic malignant fi-
brous histiocytoma. The investigator assessed these
events to be unrelated or unlikely to be related (in
the case of histiocytoma) to the treatment.
DISCUSSION
The absence of sufficient keratinized gingiva may lead
to gingival recession, which in turn may result in
the loss of a portion of the cortical plate and a worsen-
ing prognosis for the integrity of the affected tooth.
Although a meta-analysis suggested that no single
clinical measure was universally acceptable to as-
sess periodontal treatment outcomes,19 the objective
standard of ‡2 mm keratinized gingiva in mucogingi-
val procedures is generally accepted. In this study,
we evaluate the utility of an LCC to regenerate kerati-
nized gingiva when applied to a wound bed in which
the mucosa or keratinized gingiva are removed. The
use of the LCC gave a 95.3% success rate in the pri-
mary effectiveness endpoint (e.g., ‡2 mm keratinized
gingiva at month 6) (P <0.001 versus 50% standard),
and all patients achieved ‡1 mm keratinized gingiva
(P <0.001 versus 80% standard). The clinical sig-
nificance of these findings was supported by the fact
that a mean of 1.77 – 1.32 mm attached gingiva
was present at 6 months. Other endpoints, the color
and texture compared to adjacent tissue and patient
preferences, were statistically significant in favor of
the LCC (P <0.001 for all measures).
Statistically significant differences were not ob-
tained for the secondary efficacy endpoints of the
absence of pain by 3 days and a minimal surgical
sensitivity at the week-1 time point. The harvesting
of the FGG from the palate was associated with some
morbidity; however, the within-patient study design
may not have allowed for the accurate localization
of pain and sensitivity because of multiple surgical
sites within the mouth. It was also possible that the
bed preparation for LCC was somewhat larger than
the bed for FGG, which could have influenced pain-
related endpoints.
Even though FGG yielded statistically significantly
more keratinized tissue than LCC (4.57 – 1.0 mm), the
use of LCC may have several advantages compared
to the use of FGG. First, a second surgical site, the
palatal donor-site, is not required with its use, elimi-
nating pain and bleeding at the donor site. Second,
an unlimited supply of readily available material
may prevent undertreatment in situations of limited
autogenous tissue. The use of LCC provides an un-
limited amount of material to treat demanding cases
in one surgical visit. Furthermore, based on the unlim-
ited availability of the LCC, the augmentation of ker-
atinized gingiva could be indicated for extensive oral
rehabilitation cases for which the palatal tissue would
be insufficient. Third, the LCC is not a graft but affects
healing by improving the rate and quality of wound
repair by a secondary intention10,14 and, therefore, al-
lows the regeneration of a clinically relevant width of
site-appropriate (form and function) tissue that has
the same color and texture of surrounding tissues. Al-
though palatal tissue is a reliable means to generate
additional keratinized gingiva, the tissue remains
palatal, not gingival, and is often paler and of different
texture than surrounding tissue. Shrinkage is often
Table 3.
Selected Baseline Characteristics of
Surgical Sites of the mITT Cohort (n = 85)
Characteristic LCC FGG
Presence of plaque (n [%])
Buccal 18 (21) 19 (22)
Lingual 27 (32) 29 (34)
BOP (n [%]) 23 (27) 18 (21)
PD (mm)
Mean (SD) 1.39 (0.49) 1.35 (0.49)
Keratinized gingiva
width (mm)
Mean (SD) 1.41 (0.72) 1.43 (0.69)
Attached gingiva
width (mm)
Mean (SD) 0.02 (0.76) 0.08 (0.79)
Inflammation (n [%])
0 (normal) 71 (83.5) 70 (82.4)
1 (mild of any portion of
the marginal unit)
12 (14.1) 14 (16.5)
2 (mild of the entire
gingival unit)
2 (2.4) 1 (1.2)
3 (moderate) 0 (0) 0 (0)
4 (severe) 0 (0) 0 (0)
Treatment jaw (n [%])
Mandible 80 (94.1) 80 (94.1)
Maxilla 5 (5.9) 5 (5.9)
Table 4.
Amount of Soft Tissue Regenerated at
6 Months
Tissue Type LCC FGG
Keratinized gingiva (mm;
mean [SD] width)
3.21 (1.14) 4.57 (1.00)
Attached gingiva* (mm;
mean [SD])
1.77 (1.32) 3.17 (1.17)
* Prospectively collected but not identified as a primary or secondary
endpoint.
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seen with an FGG, and overcorrection is sometimes
needed, requiring a larger donor site with its inherent
morbidities.22,23 Because the LCC does not function
as a graft, and the cells of the device do not persist,
it made no sense to standardize the width of LCC to
the width of FGG. An effort was made to place as wide
a piece of the LCC as the vestibule would allow. Pa-
tients with shallow vestibules may not be good candi-
dates for this procedure.
The results from this study extend the findings from
a pilot investigation.15 However, changes from the
pilot study included the definition of a minimum size
for the Z-folded LCC of 5 · 10 mm, with deeper ves-
tibules permitted to have a wider treatment area. In
an attempt to protect the LCC, an additional single
layer of LCC was applied, which was not used in
the pilot study. The FGG with a 4-mm width was
selected to account for interpatient anatomic variabil-
ity, which sometimes limits the width of harvested
palatal tissue.21 Additionally, the 4-mm width was
used, compared to a larger width of the FGG, to min-
imize the chance of a poor esthetic outcome (color
and texture match) commonly seen with FGG proce-
dures while reliably generating a clinically relevant
amount (i.e., ‡2 mm) of keratinized gingiva.
Nevertheless, the pilot study results showed the
generation of 2.4 – 1.02 mm of keratinized gingiva,
whereas the present study results showed the gen-
eration of 3.2 – 1.14 mm of keratinized gingiva. This
amount of keratinized gingiva exceeded the proposed
minimum keratinized gingiva necessary to maintain
gingival health by >1 mm.18 Eighty-one of 85 (95.3%)
patients treated with the LCC regenerated a clinically
relevant width of keratinized gingiva (i.e., ‡2 mm).
As with any study, the interpretation of these re-
sults was limited by certain aspects of the study de-
sign. Although the duration of this study was the
typical length for soft tissue studies,24-26 a longer
follow-up would have allowed us to more thoroughly
evaluate the durability of the tissue regenerated in
the presence of the LCC and whether further creeping
attachment occurred with time.27 Additional studies
need to be conducted to determine whether patients
Figure 3.
Photographs of treatment sites within a single patient taken at baseline
(A and C) and 6 months after the application of LCC (B) or FGG (D).
Table 5.
Measure (n [%]) of Color and Texture
Compared With Tissue Adjacent to the
Surgical Site in the mITT Cohort (n = 85)
at 4 Weeks and 3 and 6 Months
Study Visit LCC FGG
Color
4 weeks
More red 28 (32.9) 6 (7.1)
Equally red 56 (65.9) 41(48.2)
Less red 1 (1.2) 38 (44.7)
3 months
More red 3 (3.5) 1 (1.2)
Equally red 80 (94.1) 29 (34.1)
Less red 2 (2.4) 55 (64.7)
6 months
More red 4 (4.7) 0 (0)
Equally red 79 (92.9) 23 (27.1)
Less red 2 (2.4) 62 (72.9)
Texture
4 weeks
More firm 2 (2.4) 27 (31.8)
Equally firm 63 (74.1) 57 (67.1)
Less firm 20 (23.5) 1 (1.2)
3 months
More firm 0 (0) 37 (43.5)
Equally firm 80 (94.1) 48 (56.5)
Less firm 5 (5.9) 0 (0)
6 months
More firm 0 (0) 39 (45.9)
Equally firm 81 (95.3) 46 (54.1)
Less firm 4 (4.7) 0 (0)
All patients had ‡1 tooth treated with each therapy.
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find the benefit of not having a donor site offsets the
additional cost of the tissue-engineered device. Ad-
ditionally, because of the nature of the surgical pro-
cedures, we were unable to mask the investigators,
and although we do not believe this to be a substantial
influence, some bias in the performance of the proce-
dures may have occurred.28 Last, the use of an auto-
graft may not have been the best control to evaluate
a treatment for which the mode of healing was via
a secondary intention. However, a more appropriate
control procedure, such as the ‘‘push back tech-
nique’’29 or a gingivectomy,30 is no longer considered
a viable treatment option.
CONCLUSIONS
The results of this study suggest that LCC may be
a safe and effective alternative to the standard of
care, FGG, for restoring gingival tissue adjacent to
teeth that do not require root coverage. The treat-
ments were well tolerated, and the adverse events
reported were events typical of this type of surgery.
These positive results open the possibility of consider-
ing LCC as a treatment for oral mucosal surface de-
fects for which the regeneration of site-appropriate
tissue is required.
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